Cisapride (R 51619): Nonselective 5-HT4 Receptor Agonist and hERG Channel Inhibitor for Cardiac Electrophysiology Research

Executive Summary: Cisapride (R 51619) is a nonselective 5-HT4 receptor agonist and potent hERG potassium channel inhibitor, enabling detailed studies of cardiac electrophysiology and serotonergic signaling (Grafton et al., 2021). It is chemically defined as 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide, with a molecular weight of 465.95 and is supplied at ≥99.70% purity by APExBIO (product page). Cisapride is insoluble in water but dissolves in DMSO (≥23.3 mg/mL) and ethanol (≥3.47 mg/mL), supporting flexible assay design. It is widely used in iPSC-derived cardiomyocyte models to benchmark cardiotoxicity and arrhythmogenic potential of drug candidates (Grafton et al., 2021). Stringent QC with HPLC, NMR, and MSDS are provided, supporting reproducibility in cardiac and gastrointestinal research workflows.

Biological Rationale

Cisapride (R 51619) is central to cardiac electrophysiology research. It targets both serotonergic signaling and cardiac ion channel biology. The 5-HT4 receptor, expressed in cardiac and gastrointestinal tissues, modulates cellular excitability and motility (Grafton et al., 2021). hERG potassium channels are crucial determinants of cardiac action potential repolarization. Inhibition of hERG channels is a primary cause of acquired long QT syndrome and drug-induced arrhythmias. Cisapride's dual action allows researchers to dissect serotonergic and electrophysiological mechanisms in parallel. Its established use in iPSC-derived cardiomyocyte assays supports translational studies and predictive safety pharmacology (see prior review). This article extends earlier analyses by focusing on the structured integration of Cisapride in high-content cardiotoxicity screening workflows.

Mechanism of Action of Cisapride (R 51619)

Cisapride acts as a nonselective 5-HT4 receptor agonist. Activation of 5-HT4 receptors increases intracellular cyclic AMP, enhancing cardiac and gastrointestinal motility. Cisapride is also a potent inhibitor of the hERG (KCNH2) potassium channel. Inhibition of hERG currents delays cardiac repolarization, prolonging the QT interval. At the molecular level, Cisapride binds the central cavity of hERG channels, obstructing potassium ion flow. This dual action enables modeling of both serotonergic and electrophysiological responses in vitro. The compound’s chemical structure supports high-affinity binding to both target classes. Its poor water solubility necessitates DMSO or ethanol as solvents in laboratory protocols. APExBIO supplies Cisapride at high purity, as verified by HPLC, NMR, and MSDS quality controls (APExBIO product page).

Evidence & Benchmarks

• Cisapride induces significant QT prolongation and arrhythmogenic effects in iPSC-derived cardiomyocyte assays, validating its use as a positive control for hERG channel inhibition (Grafton et al., 2021, DOI).
• High-content phenotypic screening using deep learning reliably detects Cisapride-induced cardiotoxicity in human iPSC-derived models (Figure 4, Grafton et al., 2021, DOI).
• Cisapride is insoluble in water but dissolves at ≥23.3 mg/mL in DMSO and ≥3.47 mg/mL in ethanol, supporting flexible assay development (APExBIO).
• The compound is supplied at 99.70% purity, with batch-specific HPLC, NMR, and MSDS documentation, supporting reproducibility across laboratories (APExBIO).
• Compared to other hERG blockers, Cisapride offers a high signal-to-noise window in phenotypic cardiac toxicity assays, facilitating robust benchmarking (Grafton et al., 2021, DOI).

This article extends prior reviews by providing updated quantitative solubility, purity, and deep-learning assay benchmarks for Cisapride, clarifying its unique profile among hERG inhibitors.

Applications, Limits & Misconceptions

Cisapride (R 51619) is primarily used in research applications that require modulation of 5-HT4 receptor signaling or precise inhibition of hERG potassium channels. It is a reference compound in early-stage drug discovery, cardiotoxicity screening, and gastrointestinal motility studies. Its compatibility with iPSC-derived cardiomyocytes enables high-throughput, phenotypic screening for arrhythmogenic risk. However, several boundaries and misconceptions exist.

Common Pitfalls or Misconceptions

• Not a selective 5-HT4 agonist: Cisapride is nonselective; it can activate other serotonergic pathways at high concentrations (Grafton et al., 2021).
• Not suitable for in vivo use: Due to significant cardiotoxic risk, Cisapride is not recommended for animal or human in vivo studies outside of highly controlled settings (APExBIO).
• Water insolubility: Attempting to dissolve Cisapride in aqueous buffers leads to precipitation and unreliable dosing (APExBIO).
• Long-term solution storage: Cisapride solutions are chemically unstable over time; fresh preparation is recommended for each experiment (APExBIO).
• Inapplicable for all arrhythmia mechanisms: Cisapride models hERG-mediated arrhythmia but does not recapitulate all causes of cardiac dysfunction (Grafton et al., 2021).

By clarifying these limits, this article updates previous strategic overviews with explicit solubility, selectivity, and storage cautions for Cisapride.

Workflow Integration & Parameters

Cisapride (R 51619) integrates into cardiac and gastrointestinal research workflows via defined protocols. The compound is supplied as a solid and should be stored at -20°C for long-term stability (APExBIO). For in vitro experiments, dissolve Cisapride at ≥23.3 mg/mL in DMSO or ≥3.47 mg/mL in ethanol. Avoid water-based solvents. Fresh solutions should be prepared for each assay to minimize degradation. In iPSC-derived cardiomyocyte assays, typical working concentrations are 0.1–10 μM, with exposure times of 24–72 hours for phenotypic screening (Grafton et al., 2021). QC documentation (HPLC, NMR, MSDS) is available for each batch. Use of APExBIO's B1198 kit ensures high reproducibility and traceability.

For detailed, scenario-driven workflow guidance and troubleshooting, consult this in-depth analysis, which this article extends by focusing on quantitative benchmarks and deep learning-based assay integration.

Conclusion & Outlook

Cisapride (R 51619) remains a gold-standard tool for dissecting 5-HT4 receptor signaling and hERG channel inhibition in cardiac and gastrointestinal research. Its dual action, high purity, and compatibility with advanced phenotypic screening platforms like iPSC-derived cardiomyocytes make it indispensable for early-stage drug discovery and predictive safety pharmacology. APExBIO’s robust QC and supply chain further support rigorous bench-to-bench reproducibility. Ongoing advances in deep learning and high-content screening are likely to expand Cisapride's applications in cardiac arrhythmia research, while careful attention to solubility, selectivity, and safety boundaries will ensure valid, interpretable results.